IKT Latest Report

Financial Performance in 2024

Inhibikase (stock code: IKT) faced significant financial challenges in 2024, with its total operating revenue in negative territory, indicating serious difficulties in the market environment. Compared with 2023, its operating revenue decreased by approximately 193.5%, from -4403566 yuan to -12928700 yuan, reflecting the deterioration of the company's operating efficiency and market demand.

Key Financial Data

1. The operating revenue in 2024 was -12928700 yuan, a decrease of about 193.5% from the same period in 2023 (-4403566 yuan).

2. R&D expenses increased significantly, from 3002980 yuan in 2023 to 7193566 yuan in 2024, up by approximately 132%.

3. Marketing and sales management expenses also increased significantly, from 1400587 yuan in 2023 to 5735134 yuan, up by approximately 309%.

4. The net profit attributable to parent was -605 million yuan, an increase of 309 million yuan from the same period in 2023, reflecting further deterioration of the company's profitability.

Peer Comparison

1. Industry-wide analysis: The market demand and competitive pressure faced by the biopharmaceutical industry affected the overall sales revenue. If other companies in the industry performed relatively stably or grew, Inhibikase's significant decline indicates its lack of competitiveness.

2. Peer evaluation analysis: Compared with other companies in the industry, Inhibikase's operating revenue performance was poor. Other companies such as GYIK and Andiastar achieved growth, reflecting Inhibikase's shortcomings in market promotion and product acceptance.

Summary

Inhibikase's financial performance in 2024 showed a significant revenue decline, mainly affected by increased competition, declining product acceptance, and increased R&D expenses. The company needs to re-examine its product positioning and marketing strategies to cope with the competition and market changes in the industry.

Opportunities

1. Despite the current financial challenges, the company has increased its investment in new product development, which, if successful, may bring long-term revenue growth.

2. Industry transformation and the application of new technologies (such as artificial intelligence) may provide opportunities for the company to improve R&D efficiency and reduce costs.

3. Mergers and acquisitions with biotechnology companies may enhance the company's market competitiveness and innovation capabilities.

Risks

1. Continuous negative operating revenue may lead to a tight cash flow, affecting the company's operations and development.

2. The increase in R&D expenses may not bring corresponding revenue growth in the short term, leading to greater financial pressure for the company.

3. Uncertainty in market demand may further affect the company's sales capacity and market share.

Through the above analysis, Inhibikase needs to optimize its operational management in the short term while finding the key points of market demand to achieve sustainable business development.